Elivaldofen gene therapy instruction guide: helping patients make wise choices

Indications:

Indicated to slow the progression of neurological deficits in boys aged 4 to 17 years with early active adrenoleukodystrophy (CALD).

Mechanism of action:

ALDP (also known as ABCD1) is a key semi-ATP binding cassette transporter located in the peroxisomal membrane and is essential for β - oxidation and VLCFAs breakdown. If functional ALDP is missing, VLCFAs accumulate and integrate into the myelin, causing myelin instability, the formation of a pro-inflammatory brain environment, and triggering brain demyelination and axonal lesions. ElivaldogeneAutologous stem cell therapy uses lentiviral vector to transfer ABCD1 cDNA into autologous CD34 + Hematopoietic stem cells, modified cells transplanted into bone marrow, differentiate into monocytes that can enter the brain, and then differentiate into macrophages and brain microglia, producing functional ALDPdegrading VLCFAs, stabilizing the condition and bringing lasting curative effect. How to use:

per kilogram of body weight5.0×10⁶CD34 + cells, administered at one time by intravenous infusion

Side effects:

Patients may experience a range of systemic reactions when receivingElivaldogeneautologous stem cell therapy. Common symptoms include fever, chills, sore throat, body aches, unusual fatigue, and loss of appetite. These are usually the body's normal immune response to treatment and indicate that the immune system is actively responding to the changes caused by treatment. In addition, patients may also experience symptoms such as bruising or bleeding, skin sores, easy bruising, pale skin, cold hands and feet, dizziness or shortness of breath. These symptoms may be related to adverse reactions in the blood system or skin.

On a system-specific basis, patients may experience leg cramps, irregular heartbeats, chest discomfort, increased thirst or urination, which may be related to an imbalance in electrolyte balance or an impact on the cardiovascular system. At the same time, numbness, tingling, muscle weakness or weakness may also be symptoms of the nervous system being affected. Adverse reactions may also occur in the oral cavity and digestive system, such as ulcers, white spots in or around the mouth, difficulty swallowing or speaking, dry mouth and bad breath, changes in taste, as well as nausea, vomiting, stomach pain, constipation or diarrhea. In addition, hair loss, headaches or rashes may also be individual specific reactions to treatment, which require close attention and prompt treatment.

Warnings and precautions:

Patients need to have a complete blood count every six months and for fifteen years after treatment to detect signs of MDS as early as possible. In addition, this therapy may cause serious opportunistic infections such as cytomegalovirus reactivation, candidiasis, and bacteremia. Some patients develop long-term cytopenias, including pancytopenia, which may persist even one year after the infusion. In addition, patients may experience allergic reactions due to the use of dimethyl sulfoxide in the treatment.

Drug interactions:

During treatment, patients should avoid taking antiretroviral medications

Medication for special populations:

The safety and effectiveness of this therapy have not yet been established for children under 4 years old

Reference materials:https://www.drugs.com/mtm/elivaldogene-autotemcel.html#dosage